Adc Therapeutics SA

ADCTNYSE · USD
1.25USD0.00 (-6.72%)
115

Adc Therapeutics SA (ADCT) Covered Calls

Adc Therapeutics SA trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 5.56%, low versus the past year. ADCT's highest covered call setup is the $2.50 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 86.57% out of the money with 63 days to expiration, a 90.30% return until expiration, and a 523.16% theoretical annualized return. Across the setups shown, annualized returns run from 214.02% to 523.16% at strikes between $2.50 and $2.50, with 63 to 154 days to expiration, as of Nov 13, 2026.

Read more

Running ADCT covered calls helps you generate income from Adc Therapeutics SA shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ADCT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If ADCT stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ADCT covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ADCT covered call is worth writing.

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors.

2027-01-15632.5086.570.050.55121.0090.30523.16-3.73+0.471,5880.50
2027-04-161542.5086.570.054.90121.0090.30214.02-3.73+1.003394.85

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - Specialty & Generic
  • SectorHealthcare
  • IV Rank5.56% Low
  • Market cap (M$)176
  • 52 weeks high-74.90%
  • 52 weeks low60.26%
  • Analyst recommendationBuy
    2.20
  • Target price$2.62
    109.60% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-09
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.53
  • EPS growth next 5 years29.86%

As of Nov 16, 2026